SEC Form 4 · accession 0000899243-17-025506
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cristina Larkin
Officer — Chief Operating Officer
Period of report
Nov 6, 2017
Accepted (ET)
Nov 7, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 6, 2017 | P | 1,500 | $14.00 | A | 1,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.